Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679870 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
A Phase 2 study of Myelofibrosis, sponsored by Galecto Biotech AB.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 11
- Study locations
NCT04679870: Active Phase 2 study of Myelofibrosis, sponsored by Galecto Biotech AB.
NCT04679870 is a Phase 2 study of Myelofibrosis that is active but no longer recruiting, run by Galecto Biotech AB. The registered enrollment target is 21 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04679870, a Phase 2 study of Myelofibrosis, is active but no longer recruiting, sponsored by Galecto Biotech AB.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Primary Outcome
Incidence and severity of adverse events as reported by investigators
Conditions Studied
Interventions
- DRUG GB2064
Study Locations (11)
Other
- Woden Dermatology - Canberra
- Heinrich-Heine-University Dusseldorf - Düsseldorf
- Universitätsklinikum Heidelberg - Heidelberg
- Universität Leipzig - Leipzig
- Klinikum rechts der Isar der Technischen Universitaet Munchen - München
- University of Bologna Sant Orsola Malpighi - Bologna
- Azienda Ospedaliero-Universitaria Careggi - Florence
- ASST Grande Ospedale Metropolitano Niguarda - Milan
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano - Orbassano
- Azienda Socio-Sanitaria Territoriale dei Sette Laghi - Varese
Texas
- MD Andersson Cancer Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT04679870 still lists
NCT04679870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which GB2064 is the first listed.
NCT04679870 lists 11 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT04679870 about?
NCT04679870 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis". This study is an open label, phase IIa trial in subjects with Myelofibrosis
What is the current status of trial NCT04679870?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-06-09. Estimated completion is 2026-06-30.
What conditions does trial NCT04679870 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04679870?
The interventions under investigation include: GB2064 (DRUG).
Who is sponsoring clinical trial NCT04679870?
This trial is sponsored by Galecto Biotech AB, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04679870 being conducted?
This trial has 11 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04679870's enrollment target sits among peer trials
21 52nd of 61 higher than 8 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI